UroGen Pharma (URGN) Operating Income Growth (1y) (2018 - 2026)

UroGen Pharma (URGN) Operating Income Growth (1y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -24.89%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 2,150.96%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 80.62%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 8.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 145.20%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 UroGen Pharma 2.07 Bn 1.93 Bn 46.82 Mn 45.11%

Historic Data

Download Data
DateValue
Mar 31, 2026 45.11%
Dec 31, 2025 30.89%
Sep 30, 2025 -56.09%
Jun 30, 2025 -60.41%
Mar 31, 2025 -43.41%
Dec 31, 2024 -89.32%
Sep 30, 2024 -29.96%
Jun 30, 2024 -67.98%
Mar 31, 2024 -16.76%
Dec 31, 2023 27.97%
Sep 30, 2023 25.36%
Jun 30, 2023 17.81%
Mar 31, 2023 -0.40%
Dec 31, 2022 -1.84%
Sep 30, 2022 22.84%
Jun 30, 2022 18.00%
Mar 31, 2022 15.92%
Dec 31, 2021 26.93%
Sep 30, 2021 19.52%
Jun 30, 2021 28.23%